Focused On-demand Library for IQ calmodulin-binding motif-containing protein 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q15051

UPID:

IQCB1_HUMAN

Alternative names:

Nephrocystin-5; p53 and DNA damage-regulated IQ motif protein

Alternative UPACC:

Q15051; Q3KS08; Q3KS09; Q5DKQ7; Q8NI79; Q9BS08

Background:

IQ calmodulin-binding motif-containing protein 1, also known as Nephrocystin-5, plays a crucial role in ciliogenesis. Its function in the early steps of cilia formation is linked to its association with CEP290/NPHP6. It is also involved in the regulation of the BBSome complex integrity, essential for ciliary targeting of selected cargos, potentially implicating CEP290/NPHP6.

Therapeutic significance:

The protein's involvement in Senior-Loken syndrome 5 and Leber congenital amaurosis 10 highlights its therapeutic significance. Understanding the role of IQ calmodulin-binding motif-containing protein 1 could open doors to potential therapeutic strategies for these renal-retinal disorders, offering hope for targeted treatments.